Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Cancers | Free Full-Text | CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives | HTML
Breakthrough for Women With Advanced Breast Cancer - Monaleesa Clinical Trial
MONALEESA-3: Updated Survival
Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - Annals of Oncology
MONALEESA-3/-7 Pooled - Capsule Summary Slidesets - Breast and Gynecologic Cancers - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
Tailoring CDK4/6 Inhibitor Therapy for Advanced Breast Cancer - ppt download
Monaleesa Clinical Trials - CancerConnect
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
ESMO 2016: Press brief on the MONALEESA-2 clinical trial on breast cancer - YouTube
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
BOOG Study Center - Studie
MONALEESA clinical program: a review of ribociclib use in different clinical settings - Oncology Central
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | NEJM
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer | Novartis
MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
